1103-1109
STANDARDIZATION, FORMULATION AND EVALUATION OF COX-2 INHIBITOR FORMULATION IN SEMISOLID DOSAGE FORM SUITABLE FOR USE IN MUSCULOSKELETAL DISORDERS
Authors: Muhammad Razi Ullah Khan1, 2 , Musaddique Hussain1 , Shahid Masood Raza1 , Saeed Ur Rashid Nazir2 , Abrar Ahmed3 , Muhammad Aun3

Number of views: 521
Abstract:
Non-Steroidal Anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors, have
come to play an important role in the pharmacologic management of musculoskeletal disorders. Clinical trials
have established the efficacy of COX-2 inhibitor like Etoricoxib in Osteoarthritis, Rheumatoid Arthritis, Acute
Gouty Arthritis, Ankylosing Spondylitis, Low back pain, acute postoperative pain, and primary dysmenorrheal.
The present research has been undertaken with the aim to develop a novel semisolid dosage form of etoricoxib,
which would attenuate the gastrointestinal relater toxicities associated with oral administration. Etoricoxib is a
highly selective cyclooxygenase‐2 (cox‐2) inhibitor. In the present study, a fixed concentration of Etoricoxib
cream (2%) was prepared by using a different combination of active ingredient and excipients. To access the
efficacy of formulated cream, in-vitro evaluation including stability studies, tube extrude ability, spread ability,
pH, viscosity and rheological properties and drug diffusion studies were carried out. After in vitro evaluation of
cream formulations, the formulation was evaluated for the anti‐inflammatory and skin irritation studies. The
results obtained were encouraging and formulation containing Etoricoxib (2%) exhibited the most satisfying
results of all the parameters.
Key Words: Anti-Inflammatory, Cream, Etoricoxib, Stability studies